ImmunityBio reports Q1 revenue of $44 million, up 168% year-over-year

Go back to ImmunityBio reports Q1 revenue of $44 million, up 168% year-over-year
(NASDAQ: IBRX) Delayed: 7.32 +0.10 (1.39%)
Previous Close $7.22    52 Week High
Open $7.05    52 Week Low
Day High $7.60    P/E N/A 
Day Low $7.00    EPS
Volume 11,307,314